FDA Drug Safety Podcast: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
FDA Drug Safety Podcast: FDA warns about increased risk of cancer relapse with long-term use of azithromycin (Zithromax, Zmax) antibiotic after donor stem cell transplant
FDA Drug Safety podcast on azithromycin (Zithromax, Zmax) antibiotic (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
FDA Drug Safety Podcast: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
FDA Drug Safety Podcast: FDA warns about serious bleeding risk with over-the-counter antacid products containing aspirin
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
FDA Drug Safety Podcast: SFDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering
On April 9, 2019 FDA announced we have received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - April 17, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
